Header

UZH-Logo

Maintenance Infos

Cost-effectiveness and budget impact of docetaxel, abiraterone, enzalutamide, apalutamide or radiotherapy plus androgen deprivation therapy versus androgen deprivation therapy alone in newly diagnosed metastatic hormone-sensitive prostate cancer


Barbier, Michaela; Tomonaga, Yuki; Menges, Dominik; Haile, Sarah; Yebyo, Henock G; Puhan, Milo; Schwenkglenks, Matthias (2020). Cost-effectiveness and budget impact of docetaxel, abiraterone, enzalutamide, apalutamide or radiotherapy plus androgen deprivation therapy versus androgen deprivation therapy alone in newly diagnosed metastatic hormone-sensitive prostate cancer. Schweiz: Swiss Medical Board.

Statistics

Downloads

6 downloads since deposited on 13 Jan 2021
6 downloads since 12 months
Detailed statistics

Additional indexing

Item Type:Published Research Report
Communities & Collections:04 Faculty of Medicine > Epidemiology, Biostatistics and Prevention Institute (EBPI)
Dewey Decimal Classification:610 Medicine & health
Language:English
Date:6 July 2020
Deposited On:13 Jan 2021 13:42
Last Modified:13 Jan 2021 13:44
Publisher:Swiss Medical Board
Number of Pages:12
Additional Information:Health economic analysis plan Swiss Medical Board Health Technology Assessment Herausgeber: Swiss Medical Board und ECPM European Center for Pharmaceutical Medicine
OA Status:Green
Free access at:Official URL. An embargo period may apply.
Official URL:https://www.swissmedicalboard.ch/fileadmin/public/news/2020/HealthEconomicAnalysisPlan_smb_prostate_cancer_drugs_2020.pdf

Download

Green Open Access

Download PDF  'Cost-effectiveness and budget impact of docetaxel, abiraterone, enzalutamide, apalutamide or radiotherapy plus androgen deprivation therapy versus androgen deprivation therapy alone in newly diagnosed metastatic hormone-sensitive prostate cancer'.
Preview
Content: Published Version
Filetype: PDF
Size: 347kB